The committee emphasised that appropriate use, stakeholder engagement, and a post-listing review after three years would be critical to the sustainability of this new broad-listing model. …
Another potential turning point for immunotherapy access in Australia
February 1, 2026 Latest NewsBioPharma
Latest Video
Georgia Forrest
New Stories
-
Another potential turning point for immunotherapy access in Australia
February 1, 2026 - - Latest News -
Better Access Australia’s plan to make care fair, affordable and accountable
February 1, 2026 - - Latest News -
Pfizer calls for Budget shift, citing missed medicines and the impact of lost productivity
February 1, 2026 - - Latest News -
Vertex announces PBS listing of new once-daily treatment for cystic fibrosis
February 1, 2026 - - Latest News -
The 'Dispatched' Podcast - Episode 2, Series 5
January 30, 2026 - - Podcast -
New long-term data suggest sustained benefit of Eisai therapy in early Alzheimer’s Disease
January 30, 2026 - - Latest News -
Amgen announces leadership transition for Australia and New Zealand
January 30, 2026 - - Latest News